Anavex Life Sciences (AVXL) Competitors $10.01 -0.10 (-0.99%) As of 02:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AVXL vs. PCVX, ZLAB, AKRO, LNTH, ACLX, MENS, TLX, AAPG, PTCT, and MLTXShould you be buying Anavex Life Sciences stock or one of its competitors? The main competitors of Anavex Life Sciences include Vaxcyte (PCVX), Zai Lab (ZLAB), Akero Therapeutics (AKRO), Lantheus (LNTH), Arcellx (ACLX), Jyong Biotech (MENS), Telix Pharmaceuticals (TLX), Ascentage Pharma Group International (AAPG), PTC Therapeutics (PTCT), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry. Anavex Life Sciences vs. Its Competitors Vaxcyte Zai Lab Akero Therapeutics Lantheus Arcellx Jyong Biotech Telix Pharmaceuticals Ascentage Pharma Group International PTC Therapeutics MoonLake Immunotherapeutics Anavex Life Sciences (NASDAQ:AVXL) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability. Which has stronger valuation and earnings, AVXL or PCVX? Anavex Life Sciences is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnavex Life SciencesN/AN/A-$43M-$0.55-18.20VaxcyteN/AN/A-$463.93M-$4.11-7.95 Which has more volatility & risk, AVXL or PCVX? Anavex Life Sciences has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Do analysts recommend AVXL or PCVX? Anavex Life Sciences currently has a consensus target price of $44.00, suggesting a potential upside of 339.56%. Vaxcyte has a consensus target price of $136.50, suggesting a potential upside of 317.66%. Given Anavex Life Sciences' higher probable upside, equities analysts plainly believe Anavex Life Sciences is more favorable than Vaxcyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anavex Life Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Vaxcyte 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 Is AVXL or PCVX more profitable? Vaxcyte's return on equity of -16.85% beat Anavex Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Anavex Life SciencesN/A -45.67% -40.21% Vaxcyte N/A -16.85%-15.92% Do institutionals and insiders have more ownership in AVXL or PCVX? 31.6% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 11.4% of Anavex Life Sciences shares are held by company insiders. Comparatively, 3.1% of Vaxcyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media favor AVXL or PCVX? In the previous week, Anavex Life Sciences and Anavex Life Sciences both had 16 articles in the media. Anavex Life Sciences' average media sentiment score of 0.29 beat Vaxcyte's score of 0.28 indicating that Anavex Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anavex Life Sciences 4 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Vaxcyte 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryVaxcyte beats Anavex Life Sciences on 8 of the 13 factors compared between the two stocks. Get Anavex Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVXL vs. The Competition Export to ExcelMetricAnavex Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$859.76M$3.14B$5.70B$9.81BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-17.5620.7530.6225.55Price / SalesN/A367.71465.58116.50Price / CashN/A43.0338.2159.48Price / Book9.448.659.026.15Net Income-$43M-$54.65M$3.25B$264.98M7 Day Performance-9.66%6.66%4.83%2.81%1 Month Performance-7.91%9.59%6.81%3.20%1 Year Performance58.64%14.32%30.56%25.33% Anavex Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVXLAnavex Life Sciences3.8344 of 5 stars$10.01-1.0%$44.00+339.6%+63.7%$859.76MN/A-17.5640Earnings ReportAnalyst ForecastPCVXVaxcyte2.143 of 5 stars$29.67-0.8%$136.50+360.1%-59.2%$3.85BN/A-7.22160ZLABZai Lab2.4234 of 5 stars$34.66-0.9%$57.22+65.1%+115.0%$3.85B$398.99M-16.991,869News CoverageInsider TradeAKROAkero Therapeutics3.9585 of 5 stars$48.28-4.3%$81.57+69.0%+110.8%$3.85BN/A-24.1430News CoverageEarnings ReportInsider TradeAnalyst RevisionLNTHLantheus4.7313 of 5 stars$56.07-2.0%$114.50+104.2%-42.6%$3.81B$1.53B14.91700ACLXArcellx1.8554 of 5 stars$69.10-2.0%$114.31+65.4%+19.2%$3.81B$76.81M-20.2080MENSJyong BiotechN/A$49.56+9.3%N/AN/A$3.77BN/A0.0031News CoverageTLXTelix PharmaceuticalsN/A$10.89-4.0%$22.33+105.1%N/A$3.69B$783.21M0.00N/AUpcoming EarningsHigh Trading VolumeAAPGAscentage Pharma Group InternationalN/A$40.04-4.6%N/AN/A$3.49B$980.65M0.00600News CoverageGap UpPTCTPTC Therapeutics4.4529 of 5 stars$43.30-4.6%$70.15+62.0%+53.3%$3.44B$806.78M6.211,410MLTXMoonLake Immunotherapeutics2.5647 of 5 stars$53.38+1.9%$74.43+39.4%+16.8%$3.42BN/A-19.202Analyst Revision Related Companies and Tools Related Companies PCVX Alternatives ZLAB Alternatives AKRO Alternatives LNTH Alternatives ACLX Alternatives MENS Alternatives TLX Alternatives AAPG Alternatives PTCT Alternatives MLTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVXL) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anavex Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anavex Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access